Valneva ( (VALN) ) has provided an announcement.
On April 9, 2025, Valneva SE and LimmaTech Biologics AG announced the first vaccination in a Phase 2 infant study of their tetravalent Shigella vaccine candidate, S4V2. This study, conducted in Kenya, aims to evaluate the safety and immunogenicity of the vaccine in approximately 110 infants, with results expected in the second half of 2025. The vaccine development is supported by the Bill & Melinda Gates Foundation and has received Fast Track designation from the FDA, highlighting its potential to address a serious global health threat. The announcement marks a significant milestone in the fight against shigellosis, a leading cause of diarrheal disease worldwide, particularly affecting children under five.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
Valneva’s stock score reflects the company’s improved operational performance and positive technical momentum, offset by ongoing profitability challenges and a high P/E ratio. The earnings call provided a balanced outlook with potential future growth, but current valuation and profitability issues weigh heavily on the overall score.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with unmet medical needs. The company has a strong track record of advancing vaccines from early R&D to approvals and currently markets several proprietary travel vaccines, including the world’s first chikungunya vaccine. Valneva is also developing vaccine candidates against Lyme disease, Zika virus, and other global public health threats.
YTD Price Performance: 27.97%
Average Trading Volume: 47,071
Technical Sentiment Signal: Strong Buy
Current Market Cap: $500M
For a thorough assessment of VALN stock, go to TipRanks’ Stock Analysis page.